Sodium glucose transporter protein 2 inhibitors: Focusing on the kidney to treat type 2 diabetes

Therapeutic Advances in Endocrinology and Metabolism

Volumn 5, Issue 5, 2014, Pages 124-136

  Peene, Bernard ^a   Benhalima, Katrien ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

canagliflozin; dapagliflozin; empagliflozin; sodium glucose transporter protein 2 inhibitors; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA;

BLADDER CANCER; BLOOD PRESSURE; BODY COMPOSITION; BREAST CANCER; CANCER RISK; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; GLOMERULUS FILTRATION RATE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULIN RESISTANCE; KIDNEY HYPERTROPHY; META ANALYSIS (TOPIC); MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL DIABETES; REVIEW; URINARY TRACT INFECTION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84911028030     PISSN: 20420188     EISSN: 20420196     Source Type: Journal    
DOI: 10.1177/2042018814553965     Document Type: Review

References (62)

1. Bailey C. Gross J. Hennicken D. Iqbal N. Mansfiel T. List J. (2013) Dapafloflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11: 43.
2. Bailey C. Gross J. Pieters A. Bastien A. List J. (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223–2233.
3. Bailey C. Iqbal N. T'joen C. List J. (2012) Dapagliflozin monotherapy in drug naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14: 951–959.
4. Baker W. Smyth L. Riche D. Bourret E. Chamberlin K. White W. (2014) Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8: 262–275.e9.
5. Barnett A. Mithal A. Manassie J. Jones R. Rattunde H. Woerle H. et al. (2014) Efficacy and safety of empagliflozin when added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomized, double-blind, placebo controlled trial. Lancet Diabetes Endocrinol 2: 369–384.
6. Benfield T. Jensen J. Nordestgaard B. (2007) Influence of diabetes and hyperglycemia on infectious disease hospitalization and outcome. Diabetologia 50: 549–554.
7. Bode B. Stenlöf K. Sullivan D. Fung A. Usiskin K. (2013) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41: 82–84.
8. Bolinder J. Ljunggren Ö. Kullberg J. Johansson L. Wilding J. Langkilde A. et al. (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 375: 2223–2233.
9. Bolinder J. Ljunggren Ö. Johansson L. Wilding J. Langkilde A. Sjöström C. et al. (2013) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16: 159–169.
10. Cefalu W. Leiter L. Yoon K. Arias P. Niskanen L. Xie J. et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941–950.
11. Cherney D. Perkins B. Soleymanlou N. Maione M. Lai V. Lee A. et al. (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129: 587–597.
12. Davis R. Morissey M. Peters J. Wittrup-Jensen K. Kennedy-Martin T. Currie C. (2005) Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 21: 1477–1483.
13. de Fronzo R. Davidson J. Del Prato S. (2011) The role of the kidneys in glucose homeostasis: a new path towards normalizing glycemia. Diabetes Obes Metab 14: 5–14.
14. de Leon E. Jacober S. Sobel J. Foxman B. (2002) Prevalence and risk factors for vaginal candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 21.
15. Del Prato S. (2009) Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 26: 1185–1192.
16. de Nicola L. Gabbai F. Liberti M. Sagliocca A. Conte G. Minutolo R. (2014) Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis 64: 16–24.
17. EMA (2012) Forxiga: EPAR – Public assessment report (EMA). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf (accessed 24 September 2014).
18. EMA (2013) Invokana: EPAR – Public assessment report (EAM). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf (accessed 24 September 2014).
19. EMA (2014) Jardiance: EPAR – Public assessment report (EAM). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf (accessed 24 September 2014).
20. FDA (2013) Medical review NDA 204042, approved 29 March 2013 (Invokana). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000Med R.pdf (accessed 24 September 2014).
21. FDA (2014) Medical review NDA 202293, approved 8 January 2014 (Farxiga). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000Med R.pdf (accessed 24 September 2014).
22. Ferrannini E. Berk A. Hantel S. Pinnetti S. Hach T. Woerle H. et al. (2013) Long-term safety and efficacy of empagliflozin, sitagliptin and metformin: an active-controlled, parallel group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36: 4015–4021.
23. Ferrannini E. Cushman W. (2012) Diabetes and hypertension: the bad companions. Lancet 380: 601–610.
24. Ferrannini E. Ramos S. Salsali A. Tang W. List J. (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trail. Diabetes Care 33: 2217–2224.
25. Forst T. Guthrie R. Goldenberg R. Yee J. Vijapurkar U. Meininger G. et al. (2014) Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 16: 467–477.
26. Geerlings S. Fonseca V. Castro-Diaz D. List J. Parikh S. (2014) Genital and urinary tract infections in diabetes: impact of pharmacologically induced glucosuria. Diabetes Res Clin Pract 103: 373–381.
27. Gembardt F. Bartaun C. Jarzebska N. Mayoux E. Todorov V. Hohenstein B. et al. (2014) The SGLT 2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTRB ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307: F317–F325.
28. Gilbert R. (2013) Sodium-glucose linked transporter 2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int 20 November 2013 [Epub ahead of print].
29. Go A. Mozaffarian D. Roger V. Benjamin E. Berry J. Bordon W. et al. (2013) Executive summary: heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 127: 143–152.
30. Goring S. Hawkins N. Wygant G. Roudaut M. Townsend R. Wood I. et al. (2013) Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 16: 433–442.
31. Grandy S. Hashemi M. Langkilde A. Parikh S. Sjöström C. (2014) Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab 16: 645–650.
32. Grempler R. Thomas L. Eckhardt M. Himmelsbach F. Sauer A. Sharp D. et al. (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14: 83–90.
33. Guariguata L. Whiting D. Hambleton I. Beagley J. Linnenkamp U. Shaw J. (2014) Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137–149.
34. Häring H. Merker L. Seewaldt-Becker E. Weimer T. Meinicke T. Woerle H. et al. (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36: 3396–3404.
35. Henry R. Murray A. Marmolejo M. Hennicken D. Ptazynska A. List J. (2012) Dapagliflozin, metformin XR of both: initial pharmacotherapy for type 2 diabetes, a randomized controlled trial. Int J Clin Pract 66: 446–456.
36. Inzucchi S. Bergenstal R. Buse J. Diamant M. Ferrannini E. Nauck M. et al. (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55: 1577–1596.
37. Jabbour S. Hardy E. Sugg J. Parikh S. (2014) Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 37: 740–750.
38. Ji L. Ma J. Li H. Mansfield T. T'joen C. Iqbal N. et al. (2014) Dapagliflozin as monotherapy in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 36: 84–100.
39. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 a) Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 473–478.
40. Johnsson K. Ptaszynska A. Schmitz B. Sugg J. Parikh S. List J. (2013 b) Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27: 479–484.
41. Kahn S. Cooper M. Del Prato S. (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present and future. Lancet 383: 1068–1083.
42. Kohan D. Fioretto P. Tang W. List J. (2013) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962–971.
43. Kovacs C. Seshiah V. Swallow R. Jones R. Rattunde H. Woerle H. et al. (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16: 147–158.
44. Lavalle-González F. Januszewicz A. Davidson J. Tong C. Qiu R. Canovatchel W. et al. (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia 56: 2582–2592.
45. Lundkvist J. Berne C. Bolinder B. Jonsson L. (2005) The economic and quality of life impact of hypoglycemia. Eur J Health Econ 6: 197–202.
46. Molitch M. DeFronzo R. Franz M. Kean W. Mogensen C. Parving H. (2003) Diabetic nephropathy. Diabetes Care 26: S94–S98.
47. Nauck M. Del Prato S. Meier J. Duràn-García S. Rohwedder K. Elze M. et al. (2011) Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care 34: 2015–2022.
48. Rahmoune H. Thompson P. Ward J. Smith C. Hong G. Brown J. (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427–3434.
49. Roden M. Weng J. Eilbracht J. Delafont B. Kim G. Woerle H. et al. (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1: 208–219.
50. Rosenstock J. Vico M. Wei L. Salsali A. List J. (2011) Effects of dapagliflozin, an SGLT 2 inhibitor on HbA1c, body weight and hypoglycemic risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 34: 2015–2022.
51. Rosetti L. Giaccari A. DeFronzo R. (1990) Glucose toxicity. Diabetes Care 13: 610–630.
52. Rosetti L. Smith D. Shulman G. Papachristou D. DeFronza R. (1987) Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 79: 1510–1515.
53. Schernthaner G. Gross J. Rosenstock J. Guarisco M. Fu M. Yee J. et al. (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52 week randomized trial. Diabetes Care 36: 2508–2515.
54. Stenlöf K. Cefalu W. Kim K. Alba M. Usiskin K. Tong C. et al. (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15: 372–382.
55. Strojek K. Yoon K. Hruba V. ELze M. Langkilde A. Parikh S. (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13: 928–938.
56. Terami N. Ogawa D. Tachibana H. Hatanaka T. Wada J. Nakatsuka A. et al. (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PloS ONE 9: e100777.
57. Vasilakou D. Karagiannis T. Athanasiadou E. Mainou M. Liakos A. Bekiari E. et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes. A systematic review and meta-analysis. Ann Intern Med 159: 262–274.
58. Wilding J. Charpentier G. Hollander P. González-Gálvez G. Mathieu C. Vercruysse F. et al. (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomized trial. Int J Clin Pract 67: 1267–1282.
59. Wilding J. Woo V. Rohwedder K. Sugg J. Parikh S. (2014) Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 16: 124–136.
60. Wilding J. Woo V. Soler N. Pahor A. Sugg J. Rohwedder K. et al. (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med 156: 405–415.
61. Wright E. Hirayama B. Loo D. (2007) Active sugar transport in health and disease. J Intern Med 261: 32–43.
62. Yale J. Bakris G. Cariou B. Yue D. David-Neto E. Xi L. et al. (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15: 463–473.